



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

AUG 27 1998

J. Trevor Lumb
Pfizer Inc.
Patent Department
235 East 42nd Street
New York, NY 10017-5755


Re: Patent Term Extension
Application for
U.S. Patent No. 5,089,480

31

Dear Mr. Lumb:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,089,480 for a period of 527 days.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.


Karin Tyson
Legal Advisor
Special Program Law Office
Office of the Deputy Assistant Commissioner
for Patent Policy and Projects

cc: Ronald L. Wilson, Director
Health Assessment Policy Staff
Office of Health Affairs (HFY-20)
Food and Drug Administration
5600 Fishers Lane, Room 15-22
Rockville, MD 20857

RE: DECTOMAX (doramectin)
FDA Docket No.: 96E-0387

kt

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : 5,089,480
ISSUED : February 18, 1992
INVENTOR(S) : Stephen P. Gibson, et al.
PATENT OWNER : Pfizer Inc.

This is to certify that there has been presented to the

COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

527 days

from February 18, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 27th day of August 1998.


Bruce A. Lehman

Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks